NCT05360745 2026-02-11
FOODPANC
Fundacion para la Excelencia y la Calidad de la Oncologia
Phase NA Withdrawn
Clinical Trials
9 trialsNCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT07026916 2025-11-17
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 2 Withdrawn
NCT06690281 2025-09-11
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT05737615 2025-09-04
PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT05634525 2025-07-25
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT06498518 2025-07-11
PRIMUS006
University of Glasgow
Phase 2 Withdrawn
NCT02414100 2025-05-02
Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy
Thomas Jefferson University
Withdrawn
NCT05940844 2025-04-09
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
Phase 1 Withdrawn